Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Non-Current Liabilities: 2010-2024

Historic Other Non-Current Liabilities for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $772,000.

  • Anika Therapeutics' Other Non-Current Liabilities fell 5.58% to $761,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $761,000, marking a year-over-year decrease of 5.58%. This contributed to the annual value of $772,000 for FY2024, which is 91.09% up from last year.
  • Latest data reveals that Anika Therapeutics reported Other Non-Current Liabilities of $772,000 as of FY2024, which was up 91.09% from $404,000 recorded in FY2023.
  • Anika Therapeutics' 5-year Other Non-Current Liabilities high stood at $22.3 million for FY2020, and its period low was $398,000 during FY2022.
  • For the 3-year period, Anika Therapeutics' Other Non-Current Liabilities averaged around $524,667, with its median value being $404,000 (2023).
  • As far as peak fluctuations go, Anika Therapeutics' Other Non-Current Liabilities soared by 6,152.10% in 2020, and later plummeted by 94.36% in 2021.
  • Anika Therapeutics' Other Non-Current Liabilities (Yearly) stood at $22.3 million in 2020, then tumbled by 94.36% to $1.3 million in 2021, then slumped by 68.36% to $398,000 in 2022, then grew by 1.51% to $404,000 in 2023, then soared by 91.09% to $772,000 in 2024.